Cell line · CVCL_1701
Papers34
1 to 20 of 34
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| DNA-PKcs promotes therapy resistance and metastatic recurrence in neuroblastoma. | Cancer Lett | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Defining the Functional Role and Potential as an Immunotherapeutic Target of ALCAM in Neuroblastoma. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeted inhibition of WIP1 and histone H3K27 demethylase activity synergistically suppresses neuroblastoma growth. | Cell Death Dis | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Serially Quantifying TERT Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with Neuroblastoma. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting pediatric cancers via T-cell recognition of the monomorphic MHC class I-related protein MR1. | J Immunother Cancer | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Activating Transcription Factor 5 Promotes Neuroblastoma Metastasis by Inducing Anoikis Resistance. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Spatial and temporal dynamics of ATP synthase from mitochondria toward the cell surface. | Commun Biol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors. | Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma. | Int J Cancer | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Impaired Antitumor Immune Response in MYCN-amplified Neuroblastoma Is Associated with Lack of CCL2 Secretion and Poor Dendritic Cell Recruitment. | Cancer Res Commun | 2022 | Its Methods give the RRID and name the line | PubMed | |
| MYCMI-7: A Small MYC-Binding Compound that Inhibits MYC: MAX Interaction and Tumor Growth in a MYC-Dependent Manner. | Cancer Res Commun | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Translational Strategies for Repotrectinib in Neuroblastoma. | Mol Cancer Ther | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer. | Cancer Discov | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Neuroblastoma patient-derived cultures are enriched for a mesenchymal gene signature and reflect individual drug response. | Cancer Sci | 2020 | Its Methods give the RRID and name the line | PubMed | |
| Next-generation characterization of the Cancer Cell Line Encyclopedia. | Nature | 2019 | Cellosaurus cites it | PubMed | |
| Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. | Nature | 2019 | Cellosaurus cites it | PubMed | |
| An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines. | Cancer Res | 2019 | Cellosaurus cites it | PubMed | |
| Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. | Elife | 2018 | Its Methods give the RRID and name the line | PubMed | |
| Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines. | Sci Data | 2017 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1701/papers